Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 662

1.

Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies.

Wohl DA, Zeng D, Stewart P, Glomb N, Alcorn T, Jones S, Handy J, Fiscus S, Weinberg A, Gowda D, van der Horst C.

J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):538-44.

PMID:
15793363
2.

Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.

Salmon-Céron D, Mazeron MC, Chaput S, Boukli N, Senechal B, Houhou N, Katlama C, Matheron S, Fillet AM, Gozlan J, Leport C, Jeantils V, Freymuth F, Costagliola D.

AIDS. 2000 May 26;14(8):1041-9.

PMID:
10853987
3.

[Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy].

Reus S, Portilla J, Gimeno A, Sánchez-Payá J, García-Henarejos JA, Martínez-Madrid O, Usó J, Roca B, Galindo MJ, López-Aldeguer J.

Enferm Infecc Microbiol Clin. 2004 Mar;22(3):142-9. Spanish.

PMID:
14987534
4.

Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease.

Verbraak FD, Boom R, Wertheim-van Dillen PM, van den Horn GJ, Kijlstra A, de Smet MD.

Br J Ophthalmol. 1999 Oct;83(10):1186-9.

5.

Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.

Durier N, Ananworanich J, Apornpong T, Ubolyam S, Kerr SJ, Mahanontharit A, Ferradini L, Ruxrungtham K, Avihingsanon A.

Clin Infect Dis. 2013 Jul;57(1):147-55. doi: 10.1093/cid/cit173. Epub 2013 Mar 19.

PMID:
23511301
6.

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; Viral Activation Transfusion Study Investigators.

Ann Intern Med. 2001 Jul 3;135(1):17-26.

PMID:
11434728
7.

Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.

Weinberg A, Tierney C, Kendall MA, Bosch RJ, Patterson-Bartlett J, Erice A, Hirsch MS, Polsky B; AIDS Clinical Trials Group 360 Team.

J Infect Dis. 2006 Feb 15;193(4):488-93. Epub 2006 Jan 3.

PMID:
16425127
8.

Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.

Gerna G, Piccinini G, Genini E, Percivalle E, Zavattoni M, Lilleri D, Testa L, Comolli G, Maserati R, Baldanti F, Maccario R, Monforte AD, Revello MG.

J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):320-31.

PMID:
11707667
9.

Qualitative and quantitative PCR measures of cytomegalovirus in patients with advanced HIV infection who require transfusions.

Para MF, Kalish LA, Collier AC, Pollard RB, Kumar PN, Mintz L, Wallach FR, Drew WL; Viral Activation Transfusion Study (VATS) Group.

J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):320-5.

PMID:
11317072
10.

[The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].

Cartón JA, Maradona JA, de Oña M, Asensi V, Melón S, García-Alcalde ML, Rodríguez-Junquera M, Moreno-Torrico A, de Zárraga M.

Med Clin (Barc). 1999 Sep 4;113(6):205-9. Spanish.

PMID:
10472608
11.

Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. Spanish CMV-AIDS Study Group.

Casado JL, Arrizabalaga J, Montes M, Martí-Belda P, Tural C, Pinilla J, Gutierrez C, Portu J, Schuurman R, Aguirrebengoa K.

AIDS. 1999 Aug 20;13(12):1497-502.

PMID:
10465073
12.

Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy.

Gourlain K, Salmon D, Gault E, Leport C, Katlama C, Matheron S, Costagliola D, Mazeron MC, Fillet AM; Predivir Study Group; CMV AC11 Study Group.

J Med Virol. 2003 Mar;69(3):401-7.

PMID:
12526052
13.

Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy.

Deayton J, Mocroft A, Wilson P, Emery VC, Johnson MA, Griffiths PD.

AIDS. 1999 Jul 9;13(10):1203-6.

PMID:
10416523
14.

Impact of highly active antiretroviral therapy on cytomegalovirus viraemia in the absence of specific anti-cytomegalovirus therapy.

Mihăilescu R, Arama V, Paraschiv S, Streinu-Cercel A, Oţelea D, Munteanu D, Iosipenco M, Chiotan C, Benea OE, Mărdărescu M, Rădulescu M, Hristea A, Ungurianu R, Aramă SS, Cercel AS, Călin R, Băicuş C.

Rom J Intern Med. 2008;46(4):305-11.

PMID:
19480296
15.

Effect of persistent moderate viremia on disease progression during HIV therapy.

Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D'Aquila R, Mangialardi WJ, Fusco GP; Collaborations in HIV Outcomes Research/United States Project.

J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1147-54.

PMID:
15319674
16.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

PMID:
15909251
17.

Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex. Multicenter AIDS Cohort Study.

Lyles RH, Chu C, Mellors JW, Margolick JB, Detels R, Giorgi JV, Al-Shboul Q, Phair JP.

AIDS. 1999 Feb 25;13(3):341-9.

PMID:
10199224
18.

Correlates of change in cytomegalovirus viremia in patients with advanced human immunodeficiency virus infection who require transfusion.

Para MF, Kalish LA, Collier AC, Murphy EL, Drew WL; Viral Activation Transfusion Study Group.

J Infect Dis. 2001 Jun 1;183(11):1673-7. Epub 2001 Apr 27.

PMID:
11343218
19.

Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy.

Jouan M, Savès M, Tubiana R, Carcelain G, Cassoux N, Aubron-Olivier C, Fillet AM, Nciri M, Sénéchal B, Chêne G, Tural C, Lasry S, Autran B, Katlama C; RESTIMOP study team.

AIDS. 2001 Jan 5;15(1):23-31.

PMID:
11192865
20.

Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).

Erice A, Tierney C, Hirsch M, Caliendo AM, Weinberg A, Kendall MA, Polsky B; AIDS Clinical Trials Group Protocol 360 Study Team.

Clin Infect Dis. 2003 Aug 15;37(4):567-78. Epub 2003 Jul 29.

PMID:
12905142

Supplemental Content

Support Center